Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lamotrigine works by blocking channels in nerve cells that allow sodium to pass through. This appears to reduce the release of glutamate and aspartate, two chemicals in the brain that stimulate nerve activity. By dampening this excitatory signaling, lamotrigine can help prevent seizures and stabilise mood. It's approved in Australia for treating partial and generalised seizures in adults and children, as well as bipolar disorder.
The medication is broken down in the body through a process called glucuronidation, which doesn't involve the cytochrome P450 enzyme system that many other medications rely on. This means lamotrigine is less likely to interfere with how other drugs are metabolised. Its half-life—the time it takes for half the dose to leave the body—is around 29 hours when taken on its own, but this can change significantly if your family member is also taking other anticonvulsants. Carbamazepine and phenytoin shorten the half-life to about 14 hours, while sodium valproate extends it to roughly 70 hours.
The most commonly reported side effects include double vision, dizziness, unsteadiness when walking, headache, and feeling weak or tired. These tend to be more noticeable when treatment starts or the dose is adjusted.
Serious side effects are less frequent but require immediate medical attention. These include severe skin reactions known as Stevens Johnson syndrome and toxic epidermal necrolysis, which usually begin with a rash. There have also been reports of a hypersensitivity syndrome involving fever, swollen lymph nodes, facial swelling, and abnormalities in blood counts or liver function. Very rarely, lamotrigine has been associated with serious blood disorders, liver dysfunction including liver failure, and disseminated intravascular coagulation with multi-organ failure. The medication should not be used by anyone with a known allergy to lamotrigine or any ingredient in the tablets.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationEpileptic seizures Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Bipolar disorder Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“The results of neurochemical and electrophysiological studies with various in vitro and in vivo preparations indicate that lamotrigine can inhibit voltage gated sodium channels and reduce the release of glutamate, an excitatory amino acid implicated in the pathophysiology of epilepsy.”
“The mean elimination half-life is 29 hours and the pharmacokinetic profile is linear up to 450 mg, being the highest single dose tested. The half-life of lamotrigine is greatly affected by the use of concomitant medicines with a mean value of approximately 14 hours when given with enzyme inducing drugs such as carbamazepine and phenytoin, and increasing to a mean value of approximately 70 hours when co-administered with sodium valproate alone”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Lamotrigine is a sodium channel–blocking antiepileptic agent that inhibits voltage-gated sodium channels and reduces glutamate release, with additional properties that distinguish it from older sodium channel blockers, including efficacy in the depressed phase of bipolar disorder and possible sigma-receptor activity. It is approved for the treatment of partial and generalised seizures in adults and children, and for bipolar disorder. The mechanism does not rely on cytochrome P450 pathways; approximately 96% of a dose is eliminated via glucuronyl-transferase–mediated conjugation, making CYP-based drug interactions unlikely with lamotrigine as the perpetrator.
The elimination half-life is approximately 29 hours when lamotrigine is used as monotherapy, but enzyme-inducing antiepileptics such as carbamazepine and phenytoin shorten this to around 14 hours, while sodium valproate extends it to approximately 70 hours through inhibition of glucuronidation. Common adverse effects include diplopia, dizziness, ataxia, headache, and asthenia. Serious dermatological reactions—Stevens–Johnson syndrome and toxic epidermal necrolysis—are well-recognised risks, as are hypersensitivity syndrome with systemic involvement, hepatic dysfunction including hepatic failure, disseminated intravascular coagulation, multiorgan failure, aplastic anaemia, and agranulocytosis. Lamotrigine is contraindicated in individuals with known hypersensitivity to the drug or any tablet excipient.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Approximately 96% of a given dose of lamotrigine is eliminated by conjugation metabolism mediated by glucuronyl-transferases. Cytochrome P450 is not involved in the elimination of lamotrigine to any significant extent. Therefore the likelihood that lamotrigine inhibits the elimination of drugs metabolised by cytochrome P450 is low.”